IL6 and metabolic syndrome: Moreover, our recent report has shown a strong association between gut microbiota alterations, dyslipidemia, increased serum indoxyl sulfate levels, heightened oxidative stress, and elevated serum IL-6 and MCP-1 levels, which together contribute to a high three-year CVD risk in patients with ESKD [114].